Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

被引:307
作者
Huang, Wei-Sheng [1 ]
Metcalf, Chester A. [1 ]
Sundaramoorthi, Raji [1 ]
Wang, Yihan [1 ]
Zou, Dong [1 ]
Thomas, R. Mathew [1 ]
Zhu, Xiaotian [1 ]
Cai, Lisi [1 ]
Wen, David [1 ]
Liu, Shuangying [1 ]
Romero, Jan [1 ]
Qi, Jiwei [1 ]
Chen, Ingrid [1 ]
Banda, Geetha [1 ]
Lentini, Scott P. [1 ]
Das, Sasmita [1 ]
Xu, Qihong [1 ]
Keats, Jeff [1 ]
Wang, Frank [1 ]
Wardwell, Scott [1 ]
Ning, Yaoyu [1 ]
Snodgrass, Joseph T. [1 ]
Broudy, Marc I. [1 ]
Russian, Karin [1 ]
Zhou, Tianjun [1 ]
Commodore, Lois [1 ]
Narasimhan, Narayana I. [1 ]
Mohemmad, Qurish K. [1 ]
Iuliucci, John [1 ]
Rivera, Victor M. [1 ]
Dalgarno, David C. [1 ]
Sawyer, Tomi K. [1 ]
Clackson, Tim [1 ]
Shakespeare, William C. [1 ]
机构
[1] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
CHRONIC MYELOID-LEUKEMIA; CENTRAL-NERVOUS-SYSTEM; IN-VIVO ACTIVITY; TYROSINE KINASE; SELECTIVE INHIBITOR; CRYSTAL-STRUCTURE; AURORA KINASES; IMATINIB; RESISTANCE; MUTATIONS;
D O I
10.1021/jm100395q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of I1e315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC(50)s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with BCR-ABL(T315I) expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CM L, including patients refractory to all currently approved therapies.
引用
收藏
页码:4701 / 4719
页数:19
相关论文
共 56 条
[1]  
[Anonymous], [No title captured]
[2]  
ASKEW BC, 2009, Patent No. 2009094123
[3]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[4]   AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses In vitro Resistance [J].
Azam, Mohammad ;
Powers, John T. ;
Einhorn, William ;
Huang, Wei-Sheng ;
Shakespeare, William C. ;
Zhu, Xiaotian ;
Dalgarno, David ;
Clackson, Tim ;
Sawyer, Tomi K. ;
Daley, George Q. .
CHEMICAL BIOLOGY & DRUG DESIGN, 2010, 75 (02) :223-227
[5]  
Bold G., 2005, PCT Int. Appl., Patent No. [2005051366, WO2005051366]
[6]   Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity [J].
Boschelli, DH ;
Ye, F ;
Wang, YD ;
Dutia, M ;
Johnson, SL ;
Wu, BQ ;
Miller, K ;
Powell, DW ;
Yaczko, D ;
Young, M ;
Tischler, M ;
Arndt, K ;
Discafani, C ;
Etienne, C ;
Gibbons, J ;
Grod, J ;
Lucas, J ;
Weber, JM ;
Boschelli, F .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) :3965-3977
[7]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[8]   Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of tie-2 kinase [J].
Cee, Victor J. ;
Albrecht, Brian K. ;
Geuns-Meyer, Stephanie ;
Hughes, Paul ;
Bellon, Steve ;
Bready, James ;
Caenepeel, Sean ;
Chaffee, Stuart C. ;
Coxon, Angela ;
Emery, Maurice ;
Fretland, Jenne ;
Gallant, Paul ;
Gu, Yan ;
Hodous, Brian L. ;
Hoffman, Doug ;
Johnson, Rebecca E. ;
Kendall, Richard ;
Kim, Joseph L. ;
Long, Alexander M. ;
McGowan, David ;
Morrison, Michael ;
Olivieri, Philip R. ;
Patel, Vinod F. ;
Polverino, Anthony ;
Powers, David ;
Rose, Paul ;
Wang, Ling ;
Zhao, Huilin .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :627-640
[9]  
Chafee S. C., 2006, Patent No. [2006044823A2, 2006044823]
[10]   The sonogashira reaction:: A booming methodology in synthetic organic chemistry [J].
Chinchilla, Rafael ;
Najera, Carmen .
CHEMICAL REVIEWS, 2007, 107 (03) :874-922